Cinctive Capital Management LP Purchases Shares of 12,252 Charles River Laboratories International, Inc. (NYSE:CRL)

Cinctive Capital Management LP acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,252 shares of the medical research company’s stock, valued at approximately $2,262,000.

A number of other institutional investors also recently made changes to their positions in CRL. Cerity Partners LLC lifted its stake in Charles River Laboratories International by 65.9% in the third quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company’s stock worth $963,000 after purchasing an additional 1,943 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in shares of Charles River Laboratories International by 9.5% in the 3rd quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company’s stock valued at $238,000 after acquiring an additional 105 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Charles River Laboratories International by 4.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company’s stock valued at $1,933,000 after acquiring an additional 423 shares during the period. Public Sector Pension Investment Board grew its position in Charles River Laboratories International by 15.1% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company’s stock worth $449,000 after acquiring an additional 300 shares during the last quarter. Finally, Benjamin Edwards Inc. grew its position in Charles River Laboratories International by 256.5% during the 3rd quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company’s stock worth $286,000 after acquiring an additional 1,044 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 2.3 %

CRL opened at $149.30 on Thursday. The stock has a market cap of $7.63 billion, a PE ratio of 995.33, a PEG ratio of 4.54 and a beta of 1.45. The business has a 50 day moving average of $163.57 and a 200-day moving average of $181.69. Charles River Laboratories International, Inc. has a 52 week low of $142.76 and a 52 week high of $264.71. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter last year, the firm posted $2.46 earnings per share. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CRL. Bank of America dropped their price objective on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. JPMorgan Chase & Co. dropped their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a research report on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $190.00 to $170.00 in a research report on Friday, March 21st. Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Finally, William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. One analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $189.77.

Insider Buying and Selling

In other Charles River Laboratories International news, CEO James C. Foster bought 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares of the company’s stock, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).